City

Houston (1)

Seattle (1)

Overall Status

Completed (1)

Recruiting (1)

Sign in for free

Phase

phase 1 (1)

phase 1/phase 2 (1)

Sponsor

M.D. Anderson Cancer Center (1)

University of Washington (1)

Collaborator

National Cancer Institute (NCI) (1)

Intervention

rituximab (2)

cd47 antagonist alx148 (1)

cyclophosphamide (1)

doxorubicin hydrochloride (1)

laboratory biomarker analysis (1)

lenalidomide (1)

pembrolizumab (1)

prednisone (1)

vincristine sulfate (1)

Study Documents

Intervention Type

biological (2)

drug (2)

other (1)

Funder Type

Other (2)

Study Type

Interventional (2)

composite lymphoma

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular

Recruiting

Aggressive B-Cell Non-Hodgkin Lymphoma
+19 more

CD47 Antagonist ALX148
+2 more

Houston, Texas

M D Anderson Cancer Center

Aug 9, 2022

Composite Lymphoma, Grade 3b Follicular Lymphoma, Stage I DLBCL Trial in Seattle (drug, other, biological)

Completed

Composite Lymphoma
+9 more

Cyclophosphamide
+6 more

Seattle, Washington

Fred Hutch/University of Washington Cancer Consortium

Sep 22, 2020